Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who were diagnosed with primary breast cancer by core biopsy~2. Patients who have been identified as HER2 negative in the tissue obtained through core needle biopsy and have confirmed the positive / negative status of ER (Estrogen receptor) and Progesterone receptor (PR)~   * HER2 positive is defined as IHC 3+ or FISH +~3. Patinets whose TNM stage confirmed by CT or MRI (T2-T3, anyN, M0 or T1-3, N1-3, M0)~Exclusion criteria:~1. Patients who have distant metastasis~2. Patients who have cystitis or urinary obstruction~3. Patients who have history of thromboembolism or coagulation disorder~4. Patients who have Interstitial lung disease ans liver cirrhosis ( \> Child-Pugh class B)~5. Patients who have Insulin-Dependent Type II diabete mellitus

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nanoxel M (Type: EXPERIMENTAL): AC(Doxorubicin, Cyclophosphamide) followed by Nanoxel M
- Taxotere (Type: ACTIVE_COMPARATOR): AC(Doxorubicin, Cyclophosphamide) followed by Taxotere

Based on this trial design, predict the completion outcome and termination type (if applicable).